Upstream Bio, Inc. has announced pivotal Phase 3 development plans for its TSLP antagonist verekitug in severe asthma and CRSwNP. The company aims to initiate both trials in Q1 2027 with a high-dose, quarterly administration regimen targeting broad patient populations.